The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer

Breast Cancer

Volumn 8, Issue 4, 2001, Pages 321-328

  Glück, Stefan ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adjuvant chemotherapy; Anthracyclines; Breast cancer; Epirubicin

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CISPLATIN; CMF PROTOCOL; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECT; FEMALE; HUMAN; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 0035748110     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967532     Document Type: Conference Paper

References (26)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 51:15-36, 2001. (Pubitemid 32166444)
2. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 352:930-942, 1998.
3. Bonadonna G, Brusamoloina E, Valagussa P, et al: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976.
4. National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer. Bethesda, Md: National Institutes of Health; November 1-3, 2000; publication 114.
5. oldhirsch A, Click JH, Gelber RD, et al: Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Cancer Inst 90:1601-1608, 1998.
6. National Comprehensive Cancer Network: Update of the NCCN guidelines for treatment of breast cancer. Oncology 11:199-220, 1997.
7. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifennonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990. (Pubitemid 20301179)
8. Misset JL, di Palma M, Delgado M, et al: Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration. J Clin Oncol 14:1136-1145, 1996.
9. Carpenter JT, Velez-Garcia E, Aron BS, et al: Fiveyear results of a randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs. cyclophosphamide, methotrexate and fluorouracil (CMF) for node positive breast cancer: A Southeastern Cancer Study Group Study. Proc Am Soc Clin Oncol 13:66(abstract 68), 1994.
10. Budd GT, Green S, O'Bryan RM, et al: Short course FAC-M versus 1 year of CMFVP in node-positive, hormone-receptor negative breast cancer: an Intergroup Study. J Clin Oncol 13:831-839, 1995.
11. Moliterni A, Bonadonna G, Valagussa P, et al: Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9:1124-1130, 1991.
12. Hutchins L, Green S, Ravdin P, et al: CMF versus CAF with and without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow-up study in low-risk node-negative patients: first results of intergroup trial INT 0102. Proc Am Soc Clin Oncol 17:1a(abstract 2), 1998.
13. Fisher B, Anderson S, Tan-Chiu E, et al: Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 19:931-942, 2001. (Pubitemid 32176267)
14. Coombes RC, Bliss JM, Wils J, et al, for the International Collaborative Cancer Group: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. J Clin Oncol 14:35-45, 1996.
15. Levine MN, Bramwell VH, Pritchard KI, et al: Randomized trial of intensive cyclophosphamide, epirubicin, and flourouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. J Clin Oncol 16:2651-2658, 1998. (Pubitemid 28363028)
16. Mouridsen HT, Andersen J, Andersson M, et al: Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF combination with epirubicin. Proc Am Soc Clin Oncol 18:68a (abstarct 254), 1999.
17. Galligioni E, Cetto G, Crivellari D, et al: High dose epirubicin and cyclophosphamide (EC) vs cyclophosphamide, methotrexate, fluorouracil (CMF) in high risk premenopausal breast cancer patients: 5-year results of a prospective randomized trial. Breast Cancer Res Treat 64:63(abstract 230), 2000.
18. Di Leo A, Larsimont D, Beauduin M, et al: CMF or anthracycline-based adjuvant chemotherapy for nodepositive (N+) breast cancer (BC) patients (PTS): 4 year results of a Belgian randomised clinical trial with predictive markers analysis. Proc Am Soc Clin Oncol 18:69a(abstract 258), 1999.
19. French Adjuvant Study Group: Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602-611, 2001.
20. Fumoleau P, Bremond A, Kerbrat P, et al, for the French Adjuvant Study Group: Better outcome of premenopausal node-positive (N+) breast cancer patients (pts) treated with 6 cycles vs 3 cycles of adjuvant chemotherapy: eight year follow-up results of FASG 01. Proc Am Soc Clin Oncol 18:67a(abstract 252), 1999.
21. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979. (Pubitemid 10218041)
22. Praga C, Trave F, Petroccione A, et al: Anthracyclineinduced cardiotoxicity and its relevance in cancer treatment. In: Nimmo WS, Tucker GT eds, Clinical Measurement in Drug Evaluation, Wolfe Publishing, London, pp132-142, 1991.
23. Wils JA, Bliss JM, Coombes MG, et al, for the International Collaborative Cancer Group: Epirubicin plus tamoxifen versus tamoxifen alone in node-positive post menopausal patients with breast cancer: a randomized trial of the International Collaborative Cancer Group. J Clin Oncol 17:1988-1998, 1999. (Pubitemid 29318826)
24. Gehl J, Boesgaard M, Paaske T, et al: Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic. Ann Oncol 7:687-693, 1996. (Pubitemid 26323541)
25. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
26. Esposito M, Venturini M, Vannozzi MO, et al: Comparative effects of paclitaxel and docetaxel on the metabolism and pharmacokinetics of epirubicin in breast cancer patients. J Clin Oncol 17:1132-1440, 1999.